Patients who have exhausted conventional options now have a pathway forward
En los márgenes de la medicina convencional, donde los tratamientos estándar han agotado su eficacia, Andalucía avanza en la construcción de una nueva frontera terapéutica. El proyecto CART-Andalucía, respaldado por 4,2 millones de euros europeos, ha entrado en su fase preclínica con el propósito de desarrollar inmunoterapias personalizadas para pacientes con cánceres hematológicos que ya no responden a los tratamientos existentes. Es un esfuerzo que no se limita a adoptar tecnología foránea, sino a forjar capacidad propia: la región aspira a que estas terapias lleguen, algún día, a través de su sistema público de salud.
- Hay pacientes con leucemias, linfomas y mielomas para quienes la medicina actual ya no tiene respuesta, y esa urgencia humana es el motor real de este proyecto.
- La terapia CAR-T reescribe genéticamente los linfocitos T del propio paciente para que reconozcan y destruyan las células tumorales, una tecnología que ya existe en el mundo pero que Andalucía quiere desarrollar y fabricar desde dentro.
- La fase preclínica en curso somete los candidatos terapéuticos a modelos celulares y animales, un paso crítico que determinará qué variante es más eficaz y segura antes de que ningún paciente la reciba.
- El horizonte marcado es finales de 2025: para entonces, el equipo habrá seleccionado el candidato más prometedor y definido el protocolo de fabricación, abriendo la puerta a los estudios regulatorios y los ensayos clínicos.
- El proyecto no es solo ciencia: es una apuesta política y sanitaria por construir infraestructura de innovación propia en medicina personalizada, con la meta explícita de integrar estas terapias en la sanidad pública andaluza.
Andalucía ha dado un paso adelante en uno de sus proyectos médicos más ambiciosos: CART-Andalucía, una iniciativa de cuatro años financiada con 4,2 millones de euros europeos, ha entrado en la fase de ensayos preclínicos. El objetivo es desarrollar inmunoterapias CAR-T para pacientes con cánceres de sangre que han agotado las opciones convencionales.
La ciencia detrás del proyecto pertenece a la vanguardia de la medicina personalizada. Los linfocitos T del propio paciente son extraídos, modificados genéticamente para identificar y atacar células tumorales, multiplicados en laboratorio y reintroducidos en el organismo. Este enfoque ha mostrado resultados prometedores frente a leucemias, linfomas y mielomas resistentes a la quimioterapia y la radioterapia.
Lo que distingue a esta iniciativa es su vocación de autonomía: Andalucía no busca importar un tratamiento ya desarrollado, sino construir la capacidad de crearlo y fabricarlo dentro de su propio sistema. La fase preclínica actual evaluará distintos candidatos terapéuticos en modelos celulares y animales, identificando cuál ofrece mayor eficacia con menores efectos secundarios.
El consejero de salud Antonio Sanz subrayó que el proyecto responde a una necesidad real: la de pacientes para quienes la medicina actual ya no tiene respuesta. La meta no es solo científica, sino también sanitaria y social: que estas terapias puedan integrarse, eventualmente, en la cartera de servicios de la sanidad pública andaluza.
El calendario prevé que a finales de 2025 se haya seleccionado el candidato más prometedor y definido el protocolo de fabricación. Ese hito abrirá la siguiente etapa: los estudios regulatorios y los ensayos clínicos que determinarán si lo que funciona en el laboratorio puede traducirse en años de vida para quienes más lo necesitan.
Andalusia is moving forward with the second phase of an ambitious project to develop a new class of cancer treatment for patients who have exhausted conventional options. The regional government announced this week that CART-Andalucía, a four-year initiative backed by 4.2 million euros in European funding, has advanced into preclinical testing—the stage where researchers evaluate whether experimental therapies actually work before they ever reach a patient.
The science at the heart of this project is CAR-T immunotherapy, a form of personalized medicine that sounds like science fiction but is already being used in some parts of the world. The approach takes T lymphocytes—immune cells drawn from a patient's own blood—and rewires them genetically to recognize and attack cancer cells. Once modified, these cells are multiplied in the laboratory and returned to the patient, where they hunt down tumors. The method has shown particular promise against blood cancers: leukemias, lymphomas, and myelomas that have resisted standard chemotherapy and radiation.
What makes this moment significant is that Andalusia is not simply adopting an existing treatment. The region is building its own capacity to develop and manufacture these therapies from scratch. The preclinical phase now underway will test the approach in cellular models and animal studies, establishing which candidate therapy shows the most promise while minimizing side effects. This groundwork is essential. It determines whether the project can move forward to regulatory approval and, eventually, human clinical trials.
Antonío Sanz, the regional health official overseeing the initiative, framed the advance in terms of unmet need. There are patients with blood cancers who have run out of effective options under current treatment protocols. For them, the existing arsenal of medicine has failed. CAR-T represents a different approach—one that harnesses the immune system itself rather than trying to poison the cancer into submission. Sanz emphasized that the project is not merely a scientific exercise but a response to a real gap in care, with the explicit goal of eventually making such therapies available through the public health system.
The timeline is deliberate. By the end of 2025, the teams working on CART-Andalucía will have selected the most promising therapeutic candidate and defined the manufacturing protocol—the precise recipe for making the treatment reliably and safely. That completion marks the end of this phase and the beginning of the next: regulatory studies and clinical trials that will determine whether what works in the laboratory translates to benefit in actual patients.
The stakes are both scientific and human. Blood cancers are relentless. Patients who fail to respond to standard therapy face a narrowing corridor of options. CAR-T is not a cure-all—it will not work for everyone—but for some patients, it has meant remission and years of life they would not otherwise have had. Andalusia's investment suggests the region believes this approach is worth developing locally, that the innovation infrastructure and expertise required to advance personalized cancer medicine should be built within its own health system rather than imported from elsewhere.
Notable Quotes
This project maintains a clear human focus—responding to an unmet medical need of patients with blood cancers who do not obtain lasting benefits from current therapies— Antonio Sanz, regional health official
Each advance represents another step toward safer treatments potentially accessible through the public health system— Antonio Sanz
The Hearth Conversation Another angle on the story
Why does Andalusia need to develop its own CAR-T therapy when the treatment already exists elsewhere?
Because the existing therapies are expensive, often not available through public systems, and developed by private companies in other countries. Building local capacity means understanding the science deeply enough to manufacture it themselves, adapt it to their patient population, and eventually offer it as part of public healthcare.
What exactly happens in this preclinical phase they're entering now?
They're testing the therapy in cells and animal models to prove it actually works and to refine it—making it more effective and safer before any human is ever exposed to it. It's the bridge between "this is theoretically possible" and "this is ready to try in patients."
How long until patients can actually receive this treatment?
That depends on how the preclinical work goes. If all goes well, they'll have a manufacturing protocol defined by late 2025, then move into regulatory approval and clinical trials. That could take years. But the point is they're building the pathway now.
Who benefits most from this?
Patients with blood cancers—leukemias, lymphomas, myelomas—who have already failed conventional treatment. These are people who have run out of options. For them, CAR-T could mean the difference between progression and remission.
Is there a risk this doesn't work?
Of course. Preclinical testing fails all the time. But the investment suggests they believe the science is solid enough to pursue. And even if this particular approach doesn't pan out, the infrastructure and expertise they're building will serve future innovations.